These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33834043)

  • 1. PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation.
    Luquero A; Badimon L; Borrell-Pages M
    Front Cardiovasc Med; 2021; 8():639727. PubMed ID: 33834043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local effects of human PCSK9 on the atherosclerotic lesion.
    Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
    J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
    Tang ZH; Peng J; Ren Z; Yang J; Li TT; Li TH; Wang Z; Wei DH; Liu LS; Zheng XL; Jiang ZS
    Atherosclerosis; 2017 Jul; 262():113-122. PubMed ID: 28535426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 and inflammation: a review of experimental and clinical evidence.
    Momtazi-Borojeni AA; Sabouri-Rad S; Gotto AM; Pirro M; Banach M; Awan Z; Barreto GE; Sahebkar A
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):237-245. PubMed ID: 31236571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release.
    Jaén RI; Povo-Retana A; Rosales-Mendoza C; Capillas-Herrero P; Sánchez-García S; Martín-Sanz P; Mojena M; Prieto P; Boscá L
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review.
    Wu NQ; Shi HW; Li JJ
    Front Cardiovasc Med; 2022; 9():763516. PubMed ID: 35252378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PCSK9 in lipid metabolism and atherosclerosis.
    Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
    Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis.
    Cammisotto V; Baratta F; Simeone PG; Barale C; Lupia E; Galardo G; Santilli F; Russo I; Pignatelli P
    Antioxidants (Basel); 2022 Mar; 11(3):. PubMed ID: 35326219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on the Role of PCSK9 in Atherosclerosis.
    Yurtseven E; Ural D; Baysal K; Tokgözoğlu L
    J Atheroscler Thromb; 2020 Sep; 27(9):909-918. PubMed ID: 32713931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
    Hovland A; Retterstøl K; Mollnes TE; Halvorsen B; Aukrust P; Lappegård KT
    Scand Cardiovasc J; 2020 Oct; 54(5):274-279. PubMed ID: 32500743
    [No Abstract]   [Full Text] [Related]  

  • 20. PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
    Bai XQ; Peng J; Wang MM; Xiao J; Xiang Q; Ren Z; Wen HY; Jiang ZS; Tang ZH; Liu LS
    Clin Chim Acta; 2018 Aug; 483():192-196. PubMed ID: 29727700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.